|1.||Armstrong, Paul W: 9 articles (10/2014 - 04/2003)|
|2.||Mahaffey, Kenneth W: 8 articles (10/2014 - 09/2003)|
|3.||Stone, Gregg W: 7 articles (03/2015 - 03/2002)|
|4.||Granger, Christopher B: 7 articles (10/2014 - 04/2003)|
|5.||Christenson, Robert H: 7 articles (10/2014 - 04/2003)|
|6.||Mintz, Gary S: 6 articles (03/2015 - 02/2005)|
|7.||Roe, Matthew T: 6 articles (10/2014 - 01/2006)|
|8.||Topol, Eric J: 6 articles (03/2012 - 10/2003)|
|9.||Ohman, E M: 6 articles (02/2004 - 01/2000)|
|10.||Califf, R M: 6 articles (02/2004 - 01/2000)|
08/01/2010 - "In patients with a first acute myocardial infarction, cTnI value assessed at 72 h from symptom onset shows the best correlation with predischarge infarct volume as assessed by DE-CMR and is superior to cTnI and creatine kinase-myocardial band peak and total values."
07/01/1995 - "An assay for creatine kinase MB subforms has proven helpful in early detection of myocardial infarctions and has the potential to guide admissions to coronary care units. "
12/04/2012 - "This study compared prognoses of myocardial infarction related to percutaneous coronary intervention (PCI, procedural MI) using increasing creatine kinase-myocardial band (CK-MB) thresholds with spontaneous MI. "
03/15/1997 - "Hemodynamic, angiocardiographic, echocardiographic, and serial creatine kinase-MB studies revealed the electrocardiogram to be a significant predictor of location of acute myocardial infarction, prevalence of occlusive disease in coronary vessels, myocardial contractility, low ejection fraction, increased left ventricular end-diastolic pressure, and serial creatine kinase-MB."
01/01/1989 - "The primary endpoint was recurrent myocardial infarction, which was defined as an abnormal reelevation in plasma MB creatine kinase during the 14-day study period. "
10/01/2009 - "To determine plasma concentration of creatine kinase myocardial isoenzyme-MB (CK-MB), arterial blood samples were obtained immediately before ischemia, and at the end of ischemia and reperfusion. "
11/15/1995 - "Recurrent ischemia was defined as symptoms in association with electrocardiographic changes; reinfarction was defined as a reelevation of creatine kinase myocardial band isoenzyme in an appropriate clinical setting. "
08/01/1987 - "Comparison of the 14-day event rates in these 2 groups showed that the 115 patients with electrocardiographic evidence of ischemia had a higher frequency of reinfarction (20% vs 5.3%, p less than 0.001), more extensive damage as assessed by peak MB-creatine kinase levels (91 +/- 76 vs 37 +/- 19 IU/liter, p = 0.059 [Wilcoxon rank sum]) and a higher mortality rate (11.3% vs 1.5%, p = 0.001). "
10/01/2014 - "Potentially remedial causes of intestinal ischemia include blood product usage, reoperation for bleeding, and creatine kinase-MB release. "
01/01/2003 - "LAD occlusion resulted in ischemia/infarction (creatine kinase-MB levels on-pump and off-pump versus the baselines were, respectively, 17.5 +/- 1.4 mg/L versus 1.5 +/- 0.3 mg/L [P <.05 by analysis of variance and t test]; and 19.5 +/- 1.8 mg/L versus 2.1 +/- 0.4 mg/L [P < .05]) and a significant decrease in regional myocardial function in both groups (50% decrease of PRSW). "
|3.||Chest Pain (Chest Pains)
09/01/2005 - "Aborted AMI was defined as maximal creatine kinase-MB < or = 2 x upper limit of normal coupled with the presence of resolution of chest pain and 50% of ST-segment deviation within 2 hours after onset of therapy. "
09/05/2000 - "Patients presenting with chest pain within the previous 24 hours and ischemic ECG changes or creatine kinase-MB elevation were eligible for enrollment. "
06/01/2000 - "In 414 consecutive patients with no ischemic ECG changes who were triaged to a chest pain unit, cTnT and creatine kinase, MB fraction (CK-MB) were evaluated > or = 10 h after symptom onset. "
07/01/1998 - "cTnI and creatine kinase-MB fraction (CK-MB) mass concentration were collected serially during the first 48 h from onset of symptoms in 1,047 patients > or =30 years old admitted for acute chest pain. "
04/06/1998 - "The diagnostic specificity of GPBB in non-traumatic chest pain patients was comparable to creatine kinase MB. "
|4.||Myocardial Ischemia (Ischemic Heart Diseases)
10/01/2005 - "GHRP also decreased myocardial creatine kinase release in hypophysectomized rats subjected to acute myocardial ischemia. "
02/01/1999 - "We studied 74 patients with chest pain at rest, electrocardiographic evidence of myocardial ischemia, and normal (<6.7 ng/mL) values of creatine kinase-MB. "
08/01/1981 - "The early release patterns of MB-creatine kinase (CK-MB) in myocardial ischemia and infarction are largely unknown. "
01/01/2011 - "Along with the patient history, physical examination and electrocardiography, the measurement of highly sensitive and specific cardiac troponin has supplanted the former gold standard biomarker (creatine kinase-MB) to detect myocardial damage and estimate the prognosis of patients with ischemic heart disease. "
11/01/2014 - "The aim of the present study is to evaluate the diagnostic efficacy of biochemical markers creatine kinase-MB (CK-MB) and LDH in pericardial fluid for postmortem diagnosis of ischemic heart disease (IHD). "
|5.||Body Weight (Weight, Body)
06/01/2015 - "Treatment with CY (100-300 mg/kg) increased plasma levels of creatine kinase-MB isoform (CK · MB) and heart-to-body weight ratio to a significantly greater extent in GSTP-null than WT mice. "
03/01/2014 - "The ratio of murine heart weight to body weight, pathological score of myocardial tissue, serum creatine kinase-MB titers and CVB3 loading of myocardial tissue were assessed. "
12/01/1984 - "In the dog, a 4-10-fold increase in the tissue content of MB-creatine kinase was observed for heart chambers with a 40-90% increase in the ratio of ventricular weight to body weight. "
01/01/1988 - "Multiple injections of low doses of isoproterenol (ISO) resulted in an increase of heart weight/body weight ratio by 60%, and a decrease of myocardial creatine kinase activity by 25%, as compared to normal rats. "
01/01/2013 - "At all DOX doses, the short I2 treatment induced adjuvant antineoplastic effects (decreased tumor size and proliferating cell nuclear antigen level) with significant protection against body weight loss and cardiotoxicity (creatine kinase MB, cardiac lipoperoxidation, and heart damage). "
|2.||Biological Markers (Surrogate Marker)
|5.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|6.||Creatine Kinase (Creatine Phosphokinase)
|9.||Troponin T (T, Troponin)
|1.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|4.||Induced Heart Arrest (Cardioplegia)
|5.||Renal Dialysis (Hemodialysis)